Search Result

Isoforms Recommended:	Aurora B

Results for "

Aurora-B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (31) Antibiotic (3) Apoptosis (5) Autophagy (3) Bacterial (3) c-Fms (1) c-Kit (1) CDK (2) EGFR (1) FLT3 (1) GSK-3 (4) Influenza Virus (2) JAK (2) LRRK2 (1) Parasite (2) PDGFR (3) PERK (1) Polo-like Kinase (PLK) (1) PROTACs (1) Reactive Oxygen Species (1) Src (1) Syk (1) VEGFR (5)
By Research Areas:	Cancer (34) Infection (3) Inflammation/Immunology (4)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Natural
Products

Antibodies

Click Chemistry

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC₅₀s of 310 nM and 240 nM for Aurora A and *Aurora B*, respectively .

HY-10329

JNJ-7706621 2 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, *aurora-A* and *aurora-B*, respectively .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-U00304

Aurora B inhibitor 1

Aurora Kinase Cancer

Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a K_i value of <0.010 uM.

Aurora B inhibitor 1	Aurora Kinase	Cancer
Aurora B inhibitor 1 is an *Aurora B* (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a K_i value of <0.010 uM.

HY-N3634

Corylifol C	Others	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-124526

Chiauranib Ibcasertib; CS2164	VEGFR PDGFR c-Kit Aurora Kinase c-Fms	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase *Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀* values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-141512

JB170	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .

HY-10558

CYC-116

3 Publications Verification

Aurora Kinase Cancer

CYC-116 is a potent aurora A and aurora B inhibitor with K_is of 8 and 9 nM, respectively.

CYC-116 3 Publications Verification	Aurora Kinase	Cancer
CYC-116 is a potent aurora A and *aurora B* inhibitor with K_is of 8 and 9 nM, respectively.

HY-12054A

Hesperadin hydrochloride	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC₅₀ of 250 nM .

HY-111506

Aurora inhibitor 1

Aurora Kinase Cancer

Aurora inhibitor 1 is a potent Aurora inhibitor with an IC₅₀ of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively .

Aurora inhibitor 1	Aurora Kinase	Cancer
Aurora inhibitor 1 is a potent *Aurora* inhibitor with an IC₅₀ of ≤ 4 nM and ≤13 nM for Aurora A and *Aurora B* kinase, respectively .

HY-14711

Reversine 5+ Cited Publications	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, *Aurora B* and Aurora C, respectively.

HY-14574

PF-03814735 2 Publications Verification	Aurora Kinase VEGFR	Cancer
PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and *aurora B* inhibitor with IC₅₀s of 0.8 and 0.5 nM, respectively.

HY-124330

Tripolin A (E)-Tripolin A	Aurora Kinase	Others
Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC₅₀ values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively .

HY-70044

GSK-1070916 3 Publications Verification GSK-1070916A	Aurora Kinase Apoptosis	Cancer
GSK-1070916 is a potent and selective ATP-competitive inhibitor of *aurora B* and aurora C with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.

HY-N3737

Derrone	Aurora Kinase PERK Reactive Oxygen Species	Cancer
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC₅₀ values of 6 and 22.3 μM against *Aurora B* and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-147993

Aurora kinase inhibitor-10	Aurora Kinase	Cancer
Aurora kinase inhibitor-10 (Compound 6c) is an orally active *Aurora B* inhibitor with an IC₅₀ of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .

HY-10126

Barasertib-HQPA 5+ Cited Publications AZD2811; INH-34; AZD1152-HQPA	Aurora Kinase Apoptosis	Cancer
Barasertib-HQPA (AZD2811) is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells .

HY-10127

Barasertib Maximum Cited Publications 14 Publications Verification AZD1152	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .

HY-10127A

Barasertib dihydrochloride AZD1152 dihydrochloride	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells .

HY-12054

Hesperadin 5+ Cited Publications	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC₅₀ of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral .

HY-103266

TC-A 2317 hydrochloride	Aurora Kinase	Cancer
TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (K_i=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .

HY-137377

TAS-119	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive *aurora* inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive *aurora* inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-150592

Aurora Kinases-IN-2	Aurora Kinase	Cancer
Aurora Kinases-IN-2 (compound 12Aj) is a potent Aurora kinases inhibitor with IC₅₀ values of 90 and 152 nM for Aurora A and Aurora B. Aurora Kinases-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora Kinases-IN-2 can be used for cancer research .

HY-107419

NU6140 1 Publications Verification	CDK Aurora Kinase	Cancer
NU6140 is a selective CDK2-cyclin A inhibitor (IC₅₀, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and *Aurora B, with IC₅₀*s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-144075

JAK-IN-19	JAK	Inflammation/Immunology
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC₅₀=7.2 and HLF Eotaxin pIC₅₀=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC₅₀=7.0, Aurora B pIC₅₀=5.8) .

HY-131339

SP-96	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive *Aurora B* (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, *Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-B0712

Ceftriaxone 4 Publications Verification Ro 13-9904 free acid	Bacterial Antibiotic GSK-3 Aurora Kinase	Infection Inflammation/Immunology Cancer
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of *Aurora B*. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

HY-B0712A

Ceftriaxone sodium hydrate 4 Publications Verification Ro 13-9904 sodium hydrate	Bacterial Antibiotic GSK-3 Aurora Kinase	Infection Cancer
Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of *Aurora B*. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .

HY-B0712B

Ceftriaxone sodium salt 4 Publications Verification Ro 13-9904	Antibiotic GSK-3 Bacterial Aurora Kinase	Infection Inflammation/Immunology Cancer
Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of *Aurora B*. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis .

HY-15196

TAK-285 2 Publications Verification	EGFR	Cancer
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Derrone	Infection Monophenols Flavonoids Source classification Phenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Isoflavones	Aurora Kinase PERK Reactive Oxygen Species
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC₅₀ values of 6 and 22.3 μM against *Aurora B* and Aurora A, respectively. Derrone shows anti-tumor activity .

Aurora B Antibody AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12	WB, IP	Human
Aurora B Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 39 kDa, targeting to Aurora B. It can be used for WB,IP assays with tag free, in the background of Human.

JH295		Alkynes
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aurora-B

Inhibitors & Agonists

NaturalProducts

Antibodies

Click Chemistry

Natural
Products